TRIB · Trinity Biotech plc

Summary

Trinity Biotech plc announced successful clinical results for its enhanced EpiCapture™ prostate cancer test, achieving 85% AUC accuracy in a study of approximately 750 ethnically diverse patient samples using machine learning and patient ethnicity data. The company plans to commercialize the test as a Laboratory Developed Test through its New York reference laboratory, marking its entry into precision oncology diagnostics.

Key takeaways

• Clinical study evaluated enhanced EpiCapture™ on approximately 750 patient samples
• Test delivers 85% AUC clinical accuracy
• Enhanced algorithm integrates machine learning, DNA biomarkers, and patient ethnicity
• Plans to commercialize as proprietary LDT via New York State DOH-certified lab
• First entry into precision oncology diagnostics market
• Results to be submitted for peer-reviewed oncology journal publication